communiqué de presse

Updated 02/07/2026

Kurma Partners, a member of the Eurazeo Group and a shareholder of Memo Therapeutics AG, announces the sale of the biotech company to Ipsen for an amount that could reach up to €700 million

Share on

INVEST_MEMO_THERAPEUTICS_SITE.jpg
02/07/2026 - min

Information - Individual investors

Eurazeo Investment Manager (EIM) and Eurazeo Mid Cap (EMC) are merging to form Eurazeo Global Investor (EGI)

LEARN MORE